We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $118M
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$100M
AUM Growth
-$34.3M
Cap. Flow
-$33.3M
Cap. Flow %
-33.2%
Top 10 Hldgs %
26.12%
Holding
294
New
64
Increased
32
Reduced
107
Closed
85

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$5.08M
2
UNH icon
UnitedHealth
UNH
+$4.05M
3
JNJ icon
Johnson & Johnson
JNJ
+$2.82M
4
NVO
Novo Nordisk
NVO
+$2.52M
5
ABBV icon
AbbVie
ABBV
+$2.39M

Top Sells

Rank Stock Value
1
RITM icon
Rithm Capital
RITM
+$4.32M
2
HRMY icon
Harmony Biosciences
HRMY
+$3.88M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$3.12M
4
EFC
Ellington Financial
EFC
+$2.6M
5
MTG icon
MGIC Investment
MTG
+$2.54M

Sector Composition

Rank Sector Weight
1 Healthcare 54.58%
2 Real Estate 7.4%
3 Industrials 5.96%
4 Financials 5.87%
5 Technology 4.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
251
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-15,500
Closed -$1.73M
JSPR icon
252
Jasper Therapeutics
JSPR
$22.9M
– –
-17,500
Closed -$329K
KNSA icon
253
Kiniksa Pharmaceuticals
KNSA
$4.83B
– –
-11,478
Closed -$287K
KPTI icon
254
Karyopharm Therapeutics
KPTI
$168M
– –
-75,000
Closed -$934K
KROS icon
255
Keros Therapeutics
KROS
$199M
– –
-8,000
Closed -$465K
LNTH icon
256
Lantheus
LNTH
$6.82B
– –
-9,000
Closed -$988K
MDT icon
257
Medtronic
MDT
$107B
– –
-5,000
Closed -$450K
MFA
258
MFA Financial
MFA
$929M
– –
-167,725
Closed -$2.13M
MIRM icon
259
Mirum Pharmaceuticals
MIRM
$6.89B
– –
-45,000
Closed -$1.75M
MITT
260
TPG Mortgage Investment Trust
MITT
$230M
– –
-208,879
Closed -$1.57M
MLTX icon
261
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-14,000
Closed -$706K
MTG icon
262
MGIC Investment
MTG
$6.27B
– –
-99,379
Closed -$2.54M
NUVB icon
263
Nuvation Bio
NUVB
$2.24B
– –
-135,000
Closed -$309K
NUVL
264
DELISTED
Nuvalent
NUVL
– –
-7,000
Closed -$716K
ADAM
265
Adamas Trust
ADAM
$777M
– –
-200,963
Closed -$1.27M
PEN icon
266
Penumbra
PEN
$12.5B
– –
-4,000
Closed -$777K
PGNY icon
267
Progyny
PGNY
$2.44B
– –
-7,500
Closed -$126K
QQQ icon
268
Invesco QQQ Trust
QQQ
$455B
– –
-4,182
Closed -$2.04M
QQQM icon
269
Invesco NASDAQ 100 ETF
QQQM
$95.1B
– –
-10,158
Closed -$2.04M
RITM icon
270
Rithm Capital
RITM
$5.09B
– –
-380,966
Closed -$4.32M
ROIV icon
271
Roivant Sciences
ROIV
$25.2B
– –
-100,000
Closed -$1.15M
RPRX icon
272
Royalty Pharma
RPRX
$26.1B
– –
-67,500
Closed -$1.91M
RWT
273
Redwood Trust
RWT
$616M
– –
-288,343
Closed -$2.23M
SAFE
274
Safehold
SAFE
$1.19B
– –
-11,972
Closed -$314K
SGMT icon
275
Sagimet Biosciences
SGMT
$437M
– –
-185,000
Closed -$512K
8 9 10
11
12

Similar funds

AIS
Advocate Investing Services Woodbine, Maryland $118M AUM
IVGAI
Index Venture Growth Associates III St. Helier, Channel Islands, Jersey $118M AUM 64.91% 1-Year Est. Return
OIM
Oceanic Investment Management Douglas, Isle Of Man $118M AUM
TIP
Tandem Investment Partners Bordentown, New Jersey $118M AUM 15.76% 1-Year Est. Return
RCG
Ridge Creek Global Strongsville, Ohio $118M AUM
CWM
Capstone Wealth Management Billings, Montana $118M AUM
SPW
Stillwater Private Wealth Glen Mills, Pennsylvania $118M AUM
WLC
Walnut Level Capital Denver, Colorado $118M AUM 59.12% 1-Year Est. Return

AlphaCentric Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, AlphaCentric Advisors held 294 positions worth $100M, down 25% from $135M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

AlphaCentric Advisors withdrew a net $33.3M in Q4 2024, closing 85 positions and reducing 107 holdings. Its most notable exit was Rithm Capital, an estimated $4.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 58% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, AlphaCentric Advisors opened a new position in Eli Lilly worth $4.74M.

  • AlphaCentric Advisors's largest Q4 2024 buy was Eli Lilly: 6,140 shares worth $4.74M.
  • AlphaCentric Advisors added most to iShares 1-3 Year Treasury Bond ETF in Q4 2024, an estimated $2.03M increase.
  • AlphaCentric Advisors's biggest Q4 2024 reduction was Neurocrine Biosciences, cutting an estimated $2.33M.
  • AlphaCentric Advisors fully exited Rithm Capital in Q4 2024, selling an estimated $4.32M.
  • AlphaCentric Advisors's ten largest holdings make up 26% of its $100M portfolio in Q4 2024.
  • AlphaCentric Advisors opened 64 new positions and closed 85 in Q4 2024.
  • AlphaCentric Advisors's portfolio value fell 25% quarter-over-quarter to $100M.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.